Sugi Predict

Sugi Predict / Compounds / SCHEMBL1531795

SCHEMBL1531795

SCHEMBL1531795

CCOC(=O)c1csc(C(C)=O)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.62
▸ MAPT P10636 6/20 0.62
▸ NPC1 O15118 6/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ GAA P10253 3/20 0.54
▸ HSP90AA1 P07900 2/20 0.50
▸ PLA2G4A P47712 1/20 0.50
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9454202 0.90 RAB9A (0.66) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL23146276 0.87 RAB9A (0.59) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL4717848 0.87 RAB9A (0.62) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL9297546 0.87 RAB9A (0.54) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL12548708 0.85 RAB9A (0.60) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL285573 0.83 RAB9A (0.66) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL18971791 0.83 RAB9A (0.57) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL17368808 0.81 PLA2G4A (0.58) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL22452092 0.81 PLA2G4A (0.58) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL15933940 0.81 MAPT (0.51) RAB9AMAPTNPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12144864-B2 Tubulysins and protein-tubulysin conjugates REGENERON PHARMACEUTICALS, INC. (US) 2024-11-19 — — US disclosed
CN-113454097-B Tubulysin and protein-tubulysin conjugates 里珍纳龙药品有限公司 2024-08-30 — — CN disclosed
CN-118027137-A Tubulysin and protein-tubulysin conjugates 里珍纳龙药品有限公司 2024-05-14 — — CN disclosed
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds AVEXXIN AS (NO) 2023-07-04 — — US disclosed
US-20230002440-A1 ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF SEATTLE GENETICS, INC. (US) 2023-01-05 — — US disclosed
US-20230002440-A1 ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF SEATTLE GENETICS, INC. (US) 2023-01-05 — — US disclosed
US-20220323601-A1 PROCESS FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF SEAGEN INC (US) 2022-10-13 — — US disclosed
US-11389543-B2 Process for the preparation of tubulysins and intermediates thereof SEAGEN INC. (US) 2022-07-19 — — US disclosed
EP-3898651-A2 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES REGENERON PHARMACEUTICALS, INC. (US) 2021-10-27 — — EP disclosed
CN-113454097-A Tubulysins and protein-tubulysin conjugates 里珍纳龙药品有限公司 2021-09-28 — — CN disclosed
EP-2532673-A2 Tubulysine derivatives R & D Biopharmaceuticals Gmbh (DE) 2012-12-12 — — EP disclosed
US-20120129779-A1 TUBULYSINE DERIVATIVES R&D-BIOPHARMACEUTICALS GMBH (DE) 2012-05-24 — — US disclosed
US-20120129779-A1 TUBULYSINE DERIVATIVES R&D-BIOPHARMACEUTICALS GMBH (DE) 2012-05-24 — — US disclosed
US-20110200581-A1 PHARMACEUTICAL COMPOSITIONS KEMOTECH S.r.I (IT) 2011-08-18 — — US disclosed
US-20110200581-A1 PHARMACEUTICAL COMPOSITIONS KEMOTECH S.r.I (IT) 2011-08-18 — — US disclosed
US-20110200581-A1 PHARMACEUTICAL COMPOSITIONS KEMOTECH S.r.I (IT) 2011-08-18 — — US disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 — — US disclosed
EP-2292639-A1 Tubulisine derivatives as anticancer drugs Kemotech S.r.l. (IT) 2011-03-09 — — EP disclosed
EP-2292639-A1 Tubulisine derivatives as anticancer drugs Kemotech S.r.l. (IT) 2011-03-09 — — EP disclosed
WO-2008138561-A1 TUBULYSINE DERIVATIVES R & D BIOPHARMACEUTICALS GMBH (DE) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136879-A1 COMPOUND CBR1, CBR3, CCR1 RAB9A 3005/4885MAPT 4605/4885NPC1 116/4885
US-20220323601-A1 PROCESS FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF VIP, TMPRSS15, TEKT1 RAB9A 4134/4885MAPT 3180/4885NPC1 3931/4885
US-20110200581-A1 PHARMACEUTICAL COMPOSITIONS NR1H3, NR1H2, CCR8 RAB9A 2035/4885MAPT 4692/4885NPC1 2103/4885
US-20120129779-A1 TUBULYSINE DERIVATIVES GLS, TPX2, HKDC1 RAB9A 2137/4885MAPT 3668/4885NPC1 1211/4885
US-20230002440-A1 ALTERNATIVE PROCESSES FOR THE PREPARATION OF TUBULYSINS AND INTERMEDIATES THEREOF TMPRSS15, VIP, TEKT1 RAB9A 4443/4885MAPT 3445/4885NPC1 3844/4885
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds CASP1, IL1B, OXER1 RAB9A 2983/4885MAPT 2844/4885NPC1 839/4885
US-12144864-B2 Tubulysins and protein-tubulysin conjugates SDCBP, TEK, TEKT1 RAB9A 1892/4885MAPT 1053/4885NPC1 2301/4885
US-11389543-B2 Process for the preparation of tubulysins and intermediates thereof VIP, TMPRSS15, TEKT1 RAB9A 4134/4885MAPT 3180/4885NPC1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.